JP2017527557A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017527557A5 JP2017527557A5 JP2017510880A JP2017510880A JP2017527557A5 JP 2017527557 A5 JP2017527557 A5 JP 2017527557A5 JP 2017510880 A JP2017510880 A JP 2017510880A JP 2017510880 A JP2017510880 A JP 2017510880A JP 2017527557 A5 JP2017527557 A5 JP 2017527557A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- protein
- mva vector
- recombinant
- recombinant mva
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462045538P | 2014-09-03 | 2014-09-03 | |
| US62/045,538 | 2014-09-03 | ||
| US201462055154P | 2014-09-25 | 2014-09-25 | |
| US62/055,154 | 2014-09-25 | ||
| PCT/EP2015/070161 WO2016034678A2 (en) | 2014-09-03 | 2015-09-03 | Recombinant modified vaccinia virus ankara (mva) filovirus vaccine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021000975A Division JP7113924B2 (ja) | 2014-09-03 | 2021-01-06 | 組み換え改変ワクシニアウイルスアンカラ（ｍｖａ）フィロウイルスワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017527557A JP2017527557A (ja) | 2017-09-21 |
| JP2017527557A5 true JP2017527557A5 (https=) | 2018-10-11 |
| JP6823586B2 JP6823586B2 (ja) | 2021-02-03 |
Family
ID=54145734
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017510880A Active JP6823586B2 (ja) | 2014-09-03 | 2015-09-03 | 組み換え改変ワクシニアウイルスアンカラ（ｍｖａ）フィロウイルスワクチン |
| JP2021000975A Active JP7113924B2 (ja) | 2014-09-03 | 2021-01-06 | 組み換え改変ワクシニアウイルスアンカラ（ｍｖａ）フィロウイルスワクチン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021000975A Active JP7113924B2 (ja) | 2014-09-03 | 2021-01-06 | 組み換え改変ワクシニアウイルスアンカラ（ｍｖａ）フィロウイルスワクチン |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10576141B2 (https=) |
| EP (1) | EP3188752A2 (https=) |
| JP (2) | JP6823586B2 (https=) |
| KR (2) | KR102736868B1 (https=) |
| CN (2) | CN106999565B (https=) |
| AU (2) | AU2015310909B2 (https=) |
| CA (1) | CA2959105C (https=) |
| IL (2) | IL250552B (https=) |
| MX (1) | MX2017002791A (https=) |
| MY (1) | MY193417A (https=) |
| SG (2) | SG11201701506PA (https=) |
| UA (1) | UA126848C2 (https=) |
| WO (1) | WO2016034678A2 (https=) |
| ZA (1) | ZA201701077B (https=) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
| ES2655051T3 (es) | 2011-08-26 | 2018-02-16 | Wisconsin Alumni Research Foundation | Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas |
| WO2015196150A2 (en) | 2014-06-20 | 2015-12-23 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
| HUE040440T2 (hu) | 2014-11-04 | 2019-03-28 | Janssen Vaccines & Prevention Bv | Terápiás HPV16-oltóanyagok |
| EP3223723B1 (en) * | 2014-11-26 | 2020-01-08 | Neuravi Limited | A clot retrieval device for removing occlusive clot from a blood vessel |
| US11701418B2 (en) * | 2015-01-12 | 2023-07-18 | Geovax, Inc. | Replication-deficient modified vaccinia Ankara (MVA) expressing Ebola virus glycoprotein (GP) and matrix protein (VP40) |
| EP4122492A1 (en) * | 2015-02-25 | 2023-01-25 | Memorial Sloan Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| EP3283508B1 (en) | 2015-04-17 | 2021-03-17 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
| EP3402802B1 (en) * | 2016-01-08 | 2023-04-12 | Geovax, Inc. | Compositions and methods for generating an immune response to a tumor associated antigen |
| BR112018015696A2 (pt) | 2016-02-03 | 2018-12-26 | Geovax Inc | composições e métodos para gerar uma resposta imune para um flavivírus |
| CA3014435C (en) | 2016-02-19 | 2023-04-18 | Wisconsin Alumni Research Foundation (Warf) | Improved influenza b virus replication for vaccine development |
| EP4706777A2 (en) | 2016-04-15 | 2026-03-11 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| IL262365B2 (en) | 2016-04-15 | 2024-11-01 | Alpine Immune Sciences Inc | Immunomodulatory proteins ICOS ligand variants and uses thereof |
| EP3452087A1 (en) * | 2016-05-02 | 2019-03-13 | Janssen Vaccines & Prevention B.V. | Therapeutic hpv vaccine combinations |
| EP3484507A1 (en) | 2016-07-15 | 2019-05-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against a marburg virus infection |
| US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
| CA3040296A1 (en) * | 2016-10-20 | 2018-04-26 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
| JP2020511144A (ja) | 2017-03-16 | 2020-04-16 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ｐｄ−ｌ２バリアント免疫調節タンパク質及びその使用 |
| EP3596114A2 (en) | 2017-03-16 | 2020-01-22 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| US11173204B2 (en) | 2017-04-06 | 2021-11-16 | Janssen Vaccines & Prevention B.V. | MVA-BN and Ad26.ZEBOV or Ad26.filo prime-boost regimen |
| CN110603058A (zh) | 2017-05-15 | 2019-12-20 | 扬森疫苗与预防公司 | 含有病毒的稳定组合物 |
| KR102658198B1 (ko) | 2017-05-15 | 2024-04-16 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정한 바이러스 함유 조성물 |
| WO2019018501A1 (en) * | 2017-07-18 | 2019-01-24 | Geovax Inc. | COMPOSITIONS AND METHODS FOR GENERATING LASV IMMUNE RESPONSE |
| US11311612B2 (en) | 2017-09-19 | 2022-04-26 | Geovax, Inc. | Compositions and methods for generating an immune response to treat or prevent malaria |
| GB201716181D0 (en) * | 2017-10-04 | 2017-11-15 | Univ Cape Town | Recombinant mva with modified hiv-1 env |
| KR102813968B1 (ko) | 2017-10-10 | 2025-05-29 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Ctla-4 변이체 면역조절 단백질 및 이의 용도 |
| SMT202600062T1 (it) | 2017-10-18 | 2026-03-09 | Alpine Immune Sciences Inc | Proteine immunomodulatrici del ligando di icos variante e composizioni e metodi correlati |
| WO2019084310A1 (en) | 2017-10-25 | 2019-05-02 | Yoshihiro Kawaoka | HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION |
| SG11202006148UA (en) | 2018-01-03 | 2020-07-29 | Alpine Immune Sciences Inc | Multi-domain immunomodulatory proteins and methods of use thereof |
| US12343390B2 (en) * | 2018-08-07 | 2025-07-01 | Wisconsin Alumni Research Foundation (Warf) | Recombinant biologically contained filovirus vaccine |
| JP7655849B2 (ja) | 2018-08-20 | 2025-04-02 | ウィスコンシン アルムニ リサーチ ファンデイション | ヘマグルチニン（ｈａ）タンパク質内の非ドミナントエピトープに対する免疫応答を誘起するためのベクター |
| EP3847246A1 (en) | 2018-09-06 | 2021-07-14 | Bavarian Nordic A/S | Storage improved poxvirus compositions |
| CN121499810A (zh) * | 2018-09-28 | 2026-02-10 | 剑桥企业有限公司 | 疫苗和方法 |
| WO2020113141A2 (en) | 2018-11-30 | 2020-06-04 | Alpine Immune Sciences, Inc. | Cd86 variant immunomodulatory proteins and uses thereof |
| WO2020163804A1 (en) | 2019-02-08 | 2020-08-13 | Wisconsin Alumni Research Foundation (Warf) | Humanized cell line |
| US11390649B2 (en) | 2019-05-01 | 2022-07-19 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication for vaccine development |
| US11807872B2 (en) | 2019-08-27 | 2023-11-07 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized HA for replication in eggs |
| WO2021150874A1 (en) | 2020-01-24 | 2021-07-29 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized na |
| JP2023513611A (ja) | 2020-02-14 | 2023-03-31 | ゲオバックス インコーポレイテッド | Ｓａｒｓ－ｃｏｖ２に対する免疫応答を誘導するためのワクチン及びその利用 |
| US20230114464A1 (en) | 2020-03-12 | 2023-04-13 | Bavarian Nordic A/S | Conditions Improving Poxvirus Stability |
| US12290562B2 (en) | 2020-03-25 | 2025-05-06 | Wisconsin Alumni Research Foundation (Warf) | Recombinant multivalent influenza viruses |
| CN115819616B (zh) * | 2021-07-28 | 2025-04-11 | 江苏瑞科生物技术股份有限公司 | 一种基因重组vzv融合蛋白及其制备方法和应用 |
| EP4677076A1 (en) | 2023-03-10 | 2026-01-14 | Bavarian Nordic A/S | Methods of isolating poxviruses from avian cell cultures |
| AU2024234386A1 (en) | 2023-03-10 | 2025-08-28 | Bavarian Nordic A/S | Production of poxviruses from quail cell cultures |
| WO2024188801A1 (en) | 2023-03-10 | 2024-09-19 | Bavarian Nordic A/S | Use of quail cell lines for poxvirus production |
| WO2026006679A1 (en) * | 2024-06-28 | 2026-01-02 | The Regents Of The University Of California | Retroviral vectors |
| CN120795167A (zh) * | 2025-04-15 | 2025-10-17 | 佰芮慷(广州)细胞医药科技有限公司 | 一种靶向人eb病毒的嵌合抗原受体car、car-nk细胞及用途 |
| CN120843742A (zh) * | 2025-09-09 | 2025-10-28 | 军事科学院军事医学研究院军事兽医研究所 | 一种泛哺乳动物丝状病毒检测用引物组及其检测试剂盒和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003028632A2 (en) * | 2001-10-01 | 2003-04-10 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The | Development of a preventive vaccine for filovirus infection in primates |
| EP1586331B1 (en) * | 2001-10-01 | 2008-05-28 | The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health | Development of a preventive vaccine for filovirus infection in primates |
| WO2004042001A2 (en) * | 2002-05-17 | 2004-05-21 | Emory University | Virus-like particles, methods of preparation, and immonogenic compositions |
| AU2005289439B2 (en) * | 2004-09-27 | 2011-12-01 | Crucell Holland B.V. | Optimized vaccines to provide protection against Ebola and other viruses |
| GB0706912D0 (en) * | 2007-04-10 | 2007-05-16 | Isis Innovation | Novel viral vaccines |
| CA2741523C (en) * | 2008-10-24 | 2022-06-21 | Jonathan S. Towner | Human ebola virus species and compositions and methods thereof |
| CN102325888B (zh) | 2008-11-21 | 2016-09-07 | 巴法里安诺迪克有限公司 | 包含多个同源核苷酸序列的载体 |
| US9097713B2 (en) * | 2009-09-02 | 2015-08-04 | The United States Of America As Represented By The Secretary Of The Army On Behalf Of Usamrmc | Monoclonal antibodies against glycoprotein of Ebola sudan boniface virus |
| EP2560680B1 (en) * | 2010-04-16 | 2018-11-28 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Chimpanzee adenoviral vector-based filovirus vaccines |
| CA3194125A1 (en) * | 2012-04-12 | 2013-10-17 | The Trustees Of The University Of Pennsylvania | Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same |
| WO2014037124A1 (en) * | 2012-09-04 | 2014-03-13 | Bavarian Nordic A/S | Methods and compositions for enhancing vaccine immune responses |
| GB201303406D0 (en) | 2013-02-26 | 2013-04-10 | Health Prot Agency | Crimean-Congo Haemorrhagic Fever Virus Antigenic Composition |
-
2015
- 2015-09-03 EP EP15763853.7A patent/EP3188752A2/en active Pending
- 2015-09-03 US US15/508,851 patent/US10576141B2/en active Active
- 2015-09-03 JP JP2017510880A patent/JP6823586B2/ja active Active
- 2015-09-03 SG SG11201701506PA patent/SG11201701506PA/en unknown
- 2015-09-03 MY MYPI2017700483A patent/MY193417A/en unknown
- 2015-09-03 AU AU2015310909A patent/AU2015310909B2/en active Active
- 2015-09-03 UA UAA201702987A patent/UA126848C2/uk unknown
- 2015-09-03 CN CN201580047328.1A patent/CN106999565B/zh active Active
- 2015-09-03 KR KR1020177006091A patent/KR102736868B1/ko active Active
- 2015-09-03 KR KR1020237030452A patent/KR102812180B1/ko active Active
- 2015-09-03 SG SG10201901735XA patent/SG10201901735XA/en unknown
- 2015-09-03 WO PCT/EP2015/070161 patent/WO2016034678A2/en not_active Ceased
- 2015-09-03 MX MX2017002791A patent/MX2017002791A/es unknown
- 2015-09-03 CN CN202110238900.XA patent/CN112972668A/zh active Pending
- 2015-09-03 CA CA2959105A patent/CA2959105C/en active Active
-
2017
- 2017-02-12 IL IL250552A patent/IL250552B/en unknown
- 2017-02-13 ZA ZA2017/01077A patent/ZA201701077B/en unknown
-
2020
- 2020-02-27 US US16/802,805 patent/US11338030B2/en active Active
-
2021
- 2021-01-06 JP JP2021000975A patent/JP7113924B2/ja active Active
- 2021-07-28 AU AU2021209228A patent/AU2021209228A1/en not_active Abandoned
-
2022
- 2022-01-23 IL IL290052A patent/IL290052A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017527557A5 (https=) | ||
| JP7113924B2 (ja) | 組み換え改変ワクシニアウイルスアンカラ（ｍｖａ）フィロウイルスワクチン | |
| Vrba et al. | Development and applications of viral vectored vaccines to combat zoonotic and emerging public health threats | |
| Lauer et al. | Multivalent and multipathogen viral vector vaccines | |
| Sánchez-Sampedro et al. | The evolution of poxvirus vaccines | |
| Liniger et al. | Use of viral vectors for the development of vaccines | |
| Tatsis et al. | Adenoviruses as vaccine vectors | |
| Kittel et al. | Generation of an influenza A virus vector expressing biologically active human interleukin-2 from the NS gene segment | |
| US11896657B2 (en) | Replication-deficient modified vaccinia Ankara (MVA) expressing Marburg virus glycoprotein (GP) and matrix protein (VP40) | |
| Kaynarcalidan et al. | Vaccinia virus: from crude smallpox vaccines to elaborate viral vector vaccine design | |
| HRP20221474T1 (hr) | Cjepiva protiv virusa hepatitisa b | |
| JP2017515508A5 (https=) | ||
| Khattar et al. | Mucosal immunization with Newcastle disease virus vector coexpressing HIV-1 Env and Gag proteins elicits potent serum, mucosal, and cellular immune responses that protect against vaccinia virus Env and Gag challenges | |
| WO2012053646A1 (ja) | ワクシニアウイルスベクターおよびセンダイウイルスベクターからなるプライム／ブーストワクチン用ウイルスベクター | |
| US20240392257A1 (en) | Utilization of Micro-RNA for Downregulation of Cytotoxic Transgene Expression by Modified Vaccinia Virus Ankara (MVA) | |
| Nakaya et al. | Induction of cellular immune responses to simian immunodeficiency virus gag by two recombinant negative-strand RNA virus vectors | |
| JP5675789B2 (ja) | 免疫接種のための発現ベクターとしての水疱性口内炎ウイルスの異なる複数の抗原型 | |
| Medina et al. | Virulence and immune evasion strategies of FMDV: implications for vaccine design | |
| Allen et al. | mRNA vaccines encoding computationally optimized hemagglutinin elicit protective antibodies against future antigenically drifted H1N1 and H3N2 influenza viruses isolated between 2018-2020 | |
| Lawrence et al. | Comparison of heterologous prime-boost strategies against human immunodeficiency virus type 1 Gag using negative stranded RNA viruses | |
| Di et al. | The self-assembled nanoparticle-based multi-epitope influenza mRNA vaccine elicits protective immunity against H1N1 and B influenza viruses in mice | |
| US20230126396A1 (en) | Compositions and Administration of Chimeric Glycoprotein Lyssavirus Vaccines for Coverage Against Rabies | |
| Mayrhofer et al. | Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection | |
| RU2020125098A (ru) | Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита | |
| WO2009090594A2 (en) | Alphavirus based vectors |